Central Alerting System: Publication of an Interim Clinical Commissioning Policy: Remdesivir for Patients Hospitalised with COVID-19 (adults and children of 12 years and older)
6 July 2020
Following confirmation of a Conditional Marketing Authorisation (CMA) by the European Medicines Agency (EMA) for the use of remdesivir in the treatment of COVID-19, the scientific opinion given for remdesivir via the Early Access to Medicines Scheme (EAMS) put in place on 26th May 2020 has now lapsed.
From 3 July 2020, an interim clinical commissioning policy has been put in place to define routine access to remdesivir in the treatment of COVID-19 across the UK. The policy reflects the conditions of the CMA, but also includes secondary criteria to be used should there be limitations in the supply of remdesivir in the UK.
Further information can be found in the attached alert; the interim clinical commissioning policy is also attached.
Additional information:
This alert does not need to be cascaded to Primary Care.
You can view further details of this alert by clicking on the following link: View Alert. If you have any queries regarding CAS please contact the CAS Helpdesk
ENDS